By: Denise Myshko From: targetedonc.com “In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo.” When administered with carboplatin and paclitaxel,the PARP inhibitor veliparib increased progression-free survival (PFS) in patients with hormone receptor–positive breast cancer and triple-negative breast cancer (TNBC) who were positive for germline …
-
-
Peace for a Breast Cancer Survivor
-
What Would Motivate a Person to Action After a Breast Cancer Diagnosis
-
What’s on the Outside Doesn’t Really Matter to Many Breast Cancer Survivors
-
From a Breast Cancer Survivor: A Message to Telephone and Telemarketer Solicitors
-
Love After a Breast Cancer Diagnosis
